Imaging Biometrics Shares Promising Phase 1 Clinical Trial Results and Plans for Phase 2 [Video]

IQ-AI subsidiary Imaging Biometrics Medical Oncologist and Emeritus Professor at the Medical College of Wisconsin Dr. Christopher Chitambar joined Steve Darling from Proactive to provide an update on the company’s oncology-focused drug, oral gallium maltolate, as it nears the end of its Phase 1 clinical trial. This study is designed to treat groups of patients with relapsed glioblastoma brain tumors using varying doses of oral GaM over a minimum period of two months.

The primary goals are to evaluate drug toxicity, assess patient tolerance to the treatment, and establish a recommended dose for a Phase 2 clinical trial. Historically, patients with relapsed glioblastoma experience disease progression within one to six months following relapse. However, the Phase 1 trial yielded promising results, with some patients remaining on treatment without disease progression for over six months. Remarkably, one patient showed no progression for more than a year. The full results of this …